KRYS
Price
$320.13
Change
-$2.04 (-0.63%)
Updated
Oct 22 closing price
Capitalization
9.48B
10 days until earnings call
Intraday BUY SELL Signals
XCUR
Price
$1.13
Change
+$0.09 (+8.65%)
Updated
Oct 22 closing price
Capitalization
7.4M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KRYS vs XCUR

KRYS vs XCUR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KRYS vs. XCUR commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and XCUR is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for KRYS with price predictions
Oct 22, 2026

KRYS in downward trend: price dove below 50-day moving average on September 28, 2026

KRYS moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 80 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 39 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.

The 10-day moving average for KRYS crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

The Aroon Indicator for KRYS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 54 cases where KRYS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 260 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.972) is normal, around the industry mean (2.973). P/E Ratio (38.710) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for XCUR with price predictions
Oct 22, 2026

XCUR's RSI Oscillator ascends from oversold territory

The RSI Indicator for XCUR moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 38 of the 43 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 73 cases where XCUR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on XCUR as a result. In 70 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for XCUR just turned positive on October 13, 2026. Looking at past instances where XCUR's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.

Following a +13.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where XCUR advanced for three days, in 159 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

XCUR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XCUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for XCUR entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.571) is normal, around the industry mean (2.973). P/E Ratio (-0.863) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (23.641) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. XCUR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XCUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
KRYS vs XCUR: Fundamental Ratings
KRYS
XCUR
OUTLOOK RATING
1..100
693
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
9100
SMR RATING
1..100
4699
PRICE GROWTH RATING
1..100
4289
P/E GROWTH RATING
1..100
3713
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XCUR's Valuation (77) in the null industry is in the same range as KRYS (92) in the Pharmaceuticals Major industry. This means that XCUR’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for XCUR (100) in the null industry. This means that KRYS’s stock grew significantly faster than XCUR’s over the last 12 months.

KRYS's SMR Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for XCUR (99) in the null industry. This means that KRYS’s stock grew somewhat faster than XCUR’s over the last 12 months.

KRYS's Price Growth Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for XCUR (89) in the null industry. This means that KRYS’s stock grew somewhat faster than XCUR’s over the last 12 months.

XCUR's P/E Growth Rating (13) in the null industry is in the same range as KRYS (37) in the Pharmaceuticals Major industry. This means that XCUR’s stock grew similarly to KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSXCUR
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (KRYS: $320.13 vs. XCUR: $1.13)
Brand notoriety: KRYS and XCUR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 91% vs. XCUR: 1001%
Market capitalization -- KRYS: $9.48B vs. XCUR: $7.4M
KRYS [@Biotechnology] is valued at $9.48B. XCUR’s [@Biotechnology] market capitalization is $7.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green while XCUR’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • XCUR’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than XCUR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 3 TA indicator(s) are bullish while XCUR’s TA Score has 6 bullish TA indicator(s).

  • KRYS’s TA Score: 3 bullish, 6 bearish.
  • XCUR’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, XCUR is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -2.99% price change this week, while XCUR (@Biotechnology) price change was -0.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 02, 2026.

XCUR is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KRYS
Daily Signal:
Gain/Loss:
XCUR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

XCUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XCUR has been loosely correlated with XFOR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XCUR jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
+8.65%
XFOR - XCUR
34%
Loosely correlated
+6.31%
HRTX - XCUR
26%
Poorly correlated
-12.57%
NNVC - XCUR
25%
Poorly correlated
-7.95%
PLX - XCUR
25%
Poorly correlated
N/A
KRYS - XCUR
24%
Poorly correlated
-0.63%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MEDX37.080.54
+1.49%
Horizon Kinetics Medical ETF (MEDX)
XLV181.302.36
+1.32%
State Street Health Care Select Sector SPDR ETF (XLV)
TZA48.13-0.09
-0.19%
Direxion Daily Small Cap Bear 3X ETF (TZA)
INFO28.01-0.41
-1.44%
Harbor PanAgora Dynamic Large Cap Core ETF (INFO)
TDAX22.27-0.83
-3.59%
TDAQ Lift ETF (TDAX)